Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233

Eitemau Tebyg

• Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial
  gan: Mitin, Timur, et al.
  Cyhoeddwyd: (2013)
• Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233
  gan: Mak, Raymond H., et al.
  Cyhoeddwyd: (2014)
• Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06
  gan: Efstathiou, Jason A., et al.
  Cyhoeddwyd: (2009)
• Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712—A Randomized Phase II Trial
  gan: Coen, John J., et al.
  Cyhoeddwyd: (2019)
• Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder
  gan: Michaelson, M D, et al.
  Cyhoeddwyd: (2004)